MOSAIC: A model to assess the cost-effectiveness of dexamethasone for admitted COVID-19 patients in South Africa

MODEL STRATEGIESThis model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death.Two competing strategies are modelled:1. The "status quo" summarizes costs and outcomes for patients assuming usual care (no dexamethasone).2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming usual care with dexamethasone at 6mg/day over 10 days. MODEL OUTCOMESCost: mean cost (general ward and ICU) per admitted patient from the health care provider's perspective.Health outcomes: mean DALYs and deaths per admitted patient. Other: mean ICU days and inpatient days per admitted patient.

本模型评估了从入院至出院或死亡期间，对于严重和危重新冠患者的成本与结果。模型中模拟了两种竞争策略：1. '现状'策略概括了假设常规护理（无地塞米松）患者的成本与结果。2. '地塞米松'对比策略概括了假设常规护理伴随每日6mg地塞米松连续使用10天的患者的成本与结果。模型结果：成本：从医疗机构角度出发，每位入院患者的平均成本（包括普通病房和重症监护病房）。健康结果：每位入院患者的平均伤残调整生命年（DALYs）和死亡人数。其他：每位入院患者的平均重症监护病房天数和住院天数。